Key result
Percutaneous auricular nerve stimulation following knee and hip arthroplasty resulted in median average daily pain scores of 0 to 2 and median daily oxycodone use of 0 to 2.5 mg over 5 days.
Why the study?
The study was conducted to demonstrate proof-of-concept for off-label use of an auricular neuromodulation device to provide analgesia and opioid-sparing following knee and hip arthroplasties.
Does an auricular neuromodulation device provide analgesia and reduce opioid use in patients following knee and hip arthroplasty?
Case Report (n=5)
No
Does an auricular neuromodulation device provide analgesia and reduce opioid use in patients following knee and hip arthroplasty?
Auricular neuromodulation may provide effective analgesia and reduce opioid requirements following knee and hip arthroplasty.
Does not support routine clinical use; leaves open whether auricular neuromodulation reduces post-arthroplasty opioid needs.
We present a case series to demonstrate proof-of-concept for the off-label use of an auricular neuromodulation device-originally developed to treat symptoms associated with opioid withdrawal-to instead provide analgesia and opioid-sparing following knee and hip arthroplasties. Within the recovery room, an auricular neuromodulation device (near-field stimulator system 2 [NSS-2] Bridge, Masimo) was applied to 5 patients. Average daily pain at rest and while moving was a median of 0 to 2 as measured on the 0 to 10 numeric rating scale, while median daily oxycodone use was 0 to 2.5 mg until device removal at home on postoperative day 5. One patient avoided opioid use entirely.
No takes yet. Share an insight, caveat, or question.
Finneran et al. (2022) conducted a case report in Postoperative pain following knee and hip arthroplasty (n=5). Percutaneous auricular nerve stimulation (NSS-2 Bridge) was evaluated on Average daily pain at rest and while moving (0-10 NRS) and daily oxycodone use. Percutaneous auricular nerve stimulation following knee and hip arthroplasty resulted in median average daily pain scores of 0 to 2 and median daily oxycodone use of 0 to 2.5 mg over 5 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: